Invitrogen Receives Approval from Health Canada for System to Help Determine Organ Transplant Compatibility

CARLSBAD, Calif.--([ BUSINESS WIRE ])--Invitrogen, a division of Life Technologies Corporation (NASDAQ:LIFE), today announced that its DynaChip^® HLA Antibody Analysis System has received approval from Health Canada's Medical Device Bureau for the detection and identification of antibodies to human leukocyte antigen (HLA) markers, which is an essential step in determining the compatibility of organ donors.

HLA markers are proteins found on the surface of certain cells in the body. They are used by the body's immune system to identify material that is foreign, such as viruses or bacteria. HLA antibody identification is important for organ transplant donor-recipient matching because, in the case of organ donation, a patient's immune system may fight cells from the donor, causing organ failure or rejection.

The DynaChip HLA Antibody Analysis System, which received U.S. Food and Drug Administration clearance in 2008, is the only automated chip-based system for HLA antibody detection and identification. It consists of the following three parts:

The DynaChip Processor, which automates assay processing, including dispensing, incubation and washing to image detection and results analysis;
The DynaChip protein array, which allows users to test for multiple antibodies at the same time; and
The DynaChip interpretation software, which provides rapid, efficient and automated analysis.

"Health Canada has joined a growing list of medical agencies that have approved the DynaChip HLA Antibody Analysis System to help make clinical transplant decisions," said Jim Janicki, Head of Clinical Diagnostics for Life Technologies. "This system is an important tool that can help doctors make transplant decisions more quickly and accurately."

Invitrogen is a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics. Together, with Applied Biosystems ― a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis ― they are part of Life Technologies Corporation, which markets the life science industry's most comprehensive portfolio of solutions for molecular and cell biology. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.

For more information, please visit: [ www.invitrogen.com ] and [ www.appliedbiosystems.com ].

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies has historical sales of approximately $3.5 billion in 2008, employs 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of over 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: [ www.lifetechnologies.com ].

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

N@N

Invitrogen Receives Approval from Health Canada for System to Help Determine Organ Transplant Compatibility